MaxCyte, Inc. Publication of Annual Report and Accounts (0186C)
June 16 2021 - 2:01AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 0186C
MaxCyte, Inc.
16 June 2021
MaxCyte, Inc.
("MaxCyte" or the "Company")
Publication of Annual Report and Accounts
Gaithersburg, Maryland - 16 June 2021: MaxCyte (LSE: MXCT,
MXCN), a leading provider of cell-engineering platform technologies
for next generation cell-based therapies, today announces that it
has published its Annual Report and Accounts for the year ending 31
December 2020.
The Annual Report is available to view on the Company's website
at
https://investors.maxcyte.com/news-events/documents-presentations
and printed copies of the reports have been posted to those
shareholders who have elected to continue to receive paper
communications.
###
About MaxCyte
MaxCyte is a leading commercial cell-engineering company focused
on providing enabling platform technologies to advance innovative
cell-based research as well as next-generation cell therapeutic
discovery, development and commercialisation. MaxCyte's existing
customer base ranges from large biopharmaceutical companies,
including all of the top 10, and 20 of the top 25, pharmaceutical
companies based on 2020 global revenue, to hundreds of
biotechnology companies and academic centres focused on
translational research. MaxCyte has granted 13 strategic platform
licences to commercial cell therapy developers. Including these
strategic platform licences, MaxCyte has granted pre-clinical and
clinical licences to academic and industry customers covering over
an estimated 140 programmes, of which an estimated 100 programmes
are for clinical use. MaxCyte was founded in 1998 and is
headquartered in Gaithersburg, Maryland, US. For more information,
visit www.maxcyte.com.
For further information please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Amanda Murphy, Chief Financial Officer +1 301 944 1660
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited
James Black
Duncan Monteith +44 (0)20 7260 1000
Joint Corporate Broker
Stifel Nicolaus Europe Limited
Healthcare Investment Banking
Nicholas Moore / Ben Maddison /
Samira Essebiyea
Corporate Broking
Nick Adams +44 (0) 20 7710 7600
Financial PR Adviser +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-comms.com
Mary-Jane Elliott / Chris Welsh
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ACSFFFLLRSIELIL
(END) Dow Jones Newswires
June 16, 2021 02:01 ET (06:01 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024